

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**School of Medical and Allied Sciences**

Master of Pharmacy in Pharmaceutics

Mid Term Examination - Nov 2023

Duration : 90 Minutes

Max Marks : 30

**Sem I - MPH104T - Regulatory Affair**General Instructions*Answer to the specific question asked**Draw neat, labelled diagrams wherever necessary**Approved data hand books are allowed subject to verification by the Invigilator*

- 1) Define goal of regulatory affairs . K1 (2)
- 2) Demonstrate the post marketing surveillance K2 (2)
- 3) Summarize the US registration for foreign drugs. K2 (2)
- 4) Explain drug master file. K1 (2)
- 5) Explain the ANDA process differ from NDA for generic drug approval? K2 (2)
- 6) Develop the importance of drug product performance testing, both in vitro and in vivo, during the drug development process? K3 (5)
- 7) Distinguish the Bioequivalence (BE), and why is it crucial in the assessment of generic drugs? K4 (5)

**OR**

- Examine the differences in the approval process between NDA and ANDA applications? K4 (5)
- 8) Explain the How does the Code of Federal Regulations (CFR) relate to the pharmaceutical industry, and what are its key provisions?. K5 (10)

**OR**

- Justify the pharmaceutical companies outsource Bioavailability (BA) and Bioequivalence (BE) studies to Contract Research Organizations (CROs), and what are the benefits of this practice K5 (10)